BiotechTube

Genotropin

Phase 2/3Completed
0 watching 0 views this week📈 Rising
64
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Short Stature

Conditions

Short Stature

Trial Timeline

Dec 1, 2003 → Dec 1, 2017

NCT ID
NCT02879747

About Genotropin

Genotropin is a phase 2/3 stage product being developed by Pfizer for Short Stature. The current trial status is completed. This product is registered under clinical trial identifier NCT02879747. Target conditions include Short Stature.

Hype Score Breakdown

Clinical
22
Activity
15
Company
9
Novelty
7
Community
8

Clinical Trials (3)

NCT IDPhaseStatus
NCT02879747Phase 2/3Completed
NCT00420251Phase 3Completed
NCT00174408Phase 3Completed

Competing Products

20 competing products in Short Stature

See all competitors
ProductCompanyStageHype Score
somatropin + leuprorelinEli LillyPhase 3
77
Growth HormoneEli LillyApproved
85
Pancreatic EnzymeAbbViePhase 2
52
Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth HormoneAstraZenecaPhase 3
77
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)MerckPhase 1
33
Saizen® + Saizen®MerckPhase 3
77
r-metHuLeptinAmgenPhase 1
32
Somapacitan + Norditropin®Novo NordiskPhase 2
51
Somatotropin growth hormone recombinant humanPfizerApproved
84
Genotropin (somatropin)PfizerApproved
84
Genotropin + GenotropinPfizerPhase 3
76
GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatmentPfizerApproved
84
glepaglutideZealand PharmaPhase 3
74
GlepaglutideZealand PharmaPhase 3
74
ZP1848Zealand PharmaPhase 2
49
glepaglutide + PlaceboZealand PharmaPhase 3
74
GlepaglutideZealand PharmaPhase 3
74
Glepaglutide 10 mgZealand PharmaPhase 3
74
GlepaglutideZealand PharmaPhase 3
74
Nutropin [Somatropin (rDNA origin) for injection]IpsenApproved
82

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84